Jakob Albrethsen1, Hanne Frederiksen2, Anna-Maria Andersson2, Ravinder Anand-Ivell3, Loa Nordkap2, Anne Kirstine Bang2, Niels Jørgensen2, Anders Juul2. 1. Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; and Reprounion and International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet, University of Copenhagen, Section 5064, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark, Phone: (+45) 3545 5085. 2. Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; and Reprounion and International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 3. School of Biosciences, University of Nottingham, Nottingham, UK.
Abstract
BACKGROUND: The circulating level of the peptide hormone insulin-like factor 3 (INSL3) is a promising diagnostic marker reflecting Leydig cell function in the male. Few commercial immunoassays of varying quality exist. Therefore, we decided to develop and validate a precise method for quantification of INSL3 by mass spectrometry. METHODS: We developed an assay in which the INSL3 A-chain is released from the INSL3 A-B heterodimer by chemical reduction and alkylation. The alkylated INSL3 A-chain is quantitated by liquid chromatography-tandem mass spectrometry (LC-MS/MS), as substitute for serum INSL3. The method was compared to a validated and sensitive in-house serum INSL3 immunoassay using 97 serum samples from 12 healthy boys during pubertal transition. Adult levels were determined based on sera from 72 adult healthy males aged 18-40 years. RESULTS: An LC-MS/MS assay with limit of detection and limit of quantification (LOQ) of 0.06 and 0.15 ng/mL, respectively, and intra-assay CVs <9% in the relevant ranges was obtained. The LC-MS/MS compared well with the in-house immunoassay (Deming regression slope: 1.28; Pearson correlation: R=0.86). INSL3 concentrations increased with pubertal maturation in healthy boys. INSL3 concentrations were above the LOQ in all samples from the adult men. The mean (±2 SD range)for serum INSL3 concentrations in the adult men was 2.2 (0.5-3.9) ng/mL. CONCLUSIONS: We have developed a robust and sensitive method suitable for quantitation of serum INSL3 in a clinical setting using LC-MS/MS instrumentation available in modern clinical laboratories. The method paves the way for future studies into the clinical role of serum INSL3 measurements.
BACKGROUND: The circulating level of the peptide hormone insulin-like factor 3 (INSL3) is a promising diagnostic marker reflecting Leydig cell function in the male. Few commercial immunoassays of varying quality exist. Therefore, we decided to develop and validate a precise method for quantification of INSL3 by mass spectrometry. METHODS: We developed an assay in which the INSL3 A-chain is released from the INSL3 A-B heterodimer by chemical reduction and alkylation. The alkylated INSL3 A-chain is quantitated by liquid chromatography-tandem mass spectrometry (LC-MS/MS), as substitute for serum INSL3. The method was compared to a validated and sensitive in-house serum INSL3 immunoassay using 97 serum samples from 12 healthy boys during pubertal transition. Adult levels were determined based on sera from 72 adult healthy males aged 18-40 years. RESULTS: An LC-MS/MS assay with limit of detection and limit of quantification (LOQ) of 0.06 and 0.15 ng/mL, respectively, and intra-assay CVs <9% in the relevant ranges was obtained. The LC-MS/MS compared well with the in-house immunoassay (Deming regression slope: 1.28; Pearson correlation: R=0.86). INSL3 concentrations increased with pubertal maturation in healthy boys. INSL3 concentrations were above the LOQ in all samples from the adult men. The mean (±2 SD range)for serum INSL3 concentrations in the adult men was 2.2 (0.5-3.9) ng/mL. CONCLUSIONS: We have developed a robust and sensitive method suitable for quantitation of serum INSL3 in a clinical setting using LC-MS/MS instrumentation available in modern clinical laboratories. The method paves the way for future studies into the clinical role of serum INSL3 measurements.
Entities:
Keywords:
assay development; insulin-like factor 3 (INSL3); mass spectrometry
Authors: Malene Lundgaard Riis; Gabriele Matilionyte; John E Nielsen; Cecilie Melau; David Greenald; Kristine Juul Hare; Lea Langhoff Thuesen; Eva Dreisler; Kasper Aaboe; Pia Tutein Brenøe; Anna-Maria Andersson; Jakob Albrethsen; Hanne Frederiksen; Ewa Rajpert-De Meyts; Anders Juul; Rod T Mitchell; Anne Jørgensen Journal: BMC Med Date: 2022-10-20 Impact factor: 11.150
Authors: Marie Lindhardt Ljubicic; Anne Jørgensen; Lise Aksglaede; John Erik Nielsen; Jakob Albrethsen; Anders Juul; Trine Holm Johannsen Journal: Front Endocrinol (Lausanne) Date: 2021-08-10 Impact factor: 5.555
Authors: Steven M Harrison; Nicol Corbin Bush; Yi Wang; Zachary R Mucher; Armando J Lorenzo; Gwen M Grimsby; Bruce J Schlomer; Erika E Büllesbach; Linda A Baker Journal: Front Endocrinol (Lausanne) Date: 2019-09-04 Impact factor: 5.555
Authors: Ravinder Anand-Ivell; Kee Heng; Katie Severn; Leen Antonio; Gyorgy Bartfai; Felipe F Casanueva; Ilpo T Huhtaniemi; Aleksander Giwercman; Mario Maggi; Terence W O'Neill; Margus Punab; Giulia Rastrelli; Jolanta Slowikowska-Hilczer; Jos Tournoy; Dirk Vanderschueren; Frederick C W Wu; Richard Ivell Journal: Andrology Date: 2022-07-11 Impact factor: 4.456